| scholarly article | Q13442814 |
| P50 | author | Phillip P Knowles | Q114562925 |
| Judith Murray-Rust | Q124354166 | ||
| Susanne Krüger Kjaer | Q38297251 | ||
| Rizaldy P Scott | Q56015669 | ||
| Neil Q McDonald | Q88313533 | ||
| P2093 | author name string | Massimo Santoro | |
| Carlos F Ibáñez | |||
| Sarah Hanrahan | |||
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 33577-33587 | |
| P577 | publication date | 2006-08-23 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Structure and chemical inhibition of the RET tyrosine kinase domain | |
| P478 | volume | 281 |
| Q42506388 | 3D structural analysis of protein O-mannosyl kinase, POMK, a causative gene product of dystroglycanopathy. |
| Q39473623 | A chemical genetic approach demonstrates that MPK3/MPK6 activation and NADPH oxidase-mediated oxidative burst are two independent signaling events in plant immunity |
| Q27653072 | A crystallographic snapshot of tyrosine trans-phosphorylation in action |
| Q49365688 | A secondary RET mutation in the activation loop conferring resistance to vandetanib. |
| Q36822111 | Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer |
| Q35058437 | Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases |
| Q38014338 | Analysis of the regulatory and catalytic domains of PTEN-induced kinase-1 (PINK1). |
| Q38805247 | Anti-angiogenic Therapy for Retinal Disease |
| Q37699060 | Assembly and activation of neurotrophic factor receptor complexes |
| Q47705234 | Atropisomerism in medicinal chemistry: challenges and opportunities |
| Q64120437 | BCR: a promiscuous fusion partner in hematopoietic disorders |
| Q36481954 | Cancer Genes in Lung Cancer: Racial Disparities: Are There Any? |
| Q34002709 | Cancer driver mutations in protein kinase genes |
| Q35219426 | Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. |
| Q24598357 | Cell signaling by receptor tyrosine kinases |
| Q38167995 | Central role of RET in thyroid cancer |
| Q82918637 | Completing the Arc: Targeted Inhibition of RET in Medullary Thyroid Cancer |
| Q30374663 | Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. |
| Q42212503 | Considerations of Protein Subpockets in Fragment-Based Drug Design |
| Q36375125 | Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancer |
| Q42697768 | Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR. |
| Q38930336 | Diagnosis and Molecular Classification of Lung Cancer |
| Q37633558 | Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. |
| Q58044610 | Drug resistance profiles of mutations in the RET kinase domain |
| Q38725367 | Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. |
| Q47893147 | Evidence-Based Precision Oncology with the Cancer Targetome. |
| Q27679769 | FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas |
| Q34948215 | Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. |
| Q35951645 | Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology |
| Q38995699 | GM1 ganglioside enhances Ret signaling in striatum |
| Q40820055 | Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers |
| Q50067512 | Genetic and Epigenetic of Medullary Thyroid Cancer |
| Q55008552 | Genetic and Epigenetic of Medullary Thyroid Cancer. |
| Q39423921 | Harpagoside attenuates MPTP/MPP+ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line‐derived neurotrophic factor |
| Q36157907 | Heterozygous p.S811F RET gene mutation associated with renal agenesis, oligomeganephronia and total colonic aganglionosis: a case report |
| Q37135359 | High-throughput kinase profiling as a platform for drug discovery |
| Q37902072 | How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer |
| Q35763320 | Identification of Functionally Distinct TRAF Proinflammatory and Phosphatidylinositol 3-Kinase/Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (PI3K/MEK) Transforming Activities Emanating from RET/PTC Fusion Oncoprotein |
| Q35653681 | Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase |
| Q36525474 | Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies |
| Q28830947 | Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade |
| Q35261111 | Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation |
| Q89752884 | Impact of the Protein Data Bank on antineoplastic approvals |
| Q44076075 | In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach |
| Q35977327 | Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma |
| Q39027394 | Lung Cancer Biomarkers |
| Q35038893 | Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies |
| Q38010030 | Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2 |
| Q33587821 | Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update |
| Q37118544 | Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. |
| Q46925576 | Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease. |
| Q92789459 | Neurotrophic factor GDNF regulates intestinal barrier function in inflammatory bowel disease |
| Q36970334 | Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases |
| Q36949808 | New drugs in thyroid cancer |
| Q34726233 | New therapeutic approaches to treat medullary thyroid carcinoma |
| Q27681859 | Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans |
| Q38930813 | Paracrine regulation of glioma cells invasion by astrocytes is mediated by glial-derived neurotrophic factor |
| Q54577277 | Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors |
| Q37209222 | Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions |
| Q39671929 | Protein-tyrosine phosphatase SHP2 contributes to GDNF neurotrophic activity through direct binding to phospho-Tyr687 in the RET receptor tyrosine kinase. |
| Q40289950 | RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements |
| Q38190360 | RET revisited: expanding the oncogenic portfolio |
| Q36960954 | RET signaling in endocrine tumors: delving deeper into molecular mechanisms. |
| Q37650677 | RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis |
| Q30382639 | Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase |
| Q42825115 | Rare manifestation of multiple endocrine neoplasia type 2A & cutaneous lichen amyloidosis in a family with RET gene mutation |
| Q36738608 | Receptor tyrosine kinases: mechanisms of activation and signaling |
| Q35884666 | Role of vandetanib in the management of medullary thyroid cancer |
| Q35755355 | Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine |
| Q33510934 | Sequence and structure signatures of cancer mutation hotspots in protein kinases |
| Q89830056 | State-of-the-Art Strategies for Targeting RET-Dependent Cancers |
| Q36153855 | Structural and mechanistic insights into the bifunctional enzyme isocitrate dehydrogenase kinase/phosphatase AceK |
| Q24311447 | Structural basis for the recognition of c-Src by its inactivator Csk |
| Q38053785 | Structural studies of GDNF family ligands with their receptors—Insights into ligand recognition and activation of receptor tyrosine kinase RET |
| Q36555201 | Structure and Physiology of the RET Receptor Tyrosine Kinase |
| Q27678586 | Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance |
| Q92193125 | Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity |
| Q104289124 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer |
| Q47601932 | Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes |
| Q26865765 | Targeting cancer with kinase inhibitors |
| Q38728368 | Targeting the glial-derived neurotrophic factor and related molecules for controlling normal and pathologic pain |
| Q27652467 | The Structure of the Glial Cell Line-derived Neurotrophic Factor-Coreceptor Complex: INSIGHTS INTO RET SIGNALING AND HEPARIN BINDING |
| Q30381368 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| Q50085302 | The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer |
| Q38004366 | The pituitary tumor transforming gene in thyroid cancer |
| Q38614485 | Thyroid C-Cell Biology and Oncogenic Transformation. |
| Q37967112 | Vandetanib for the Treatment of Thyroid Cancer |
| Q38103781 | Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer |
| Q43510076 | Who cares for the protons? |
| Q33632891 | Zebrafish GDNF and its co-receptor GFRα1 activate the human RET receptor and promote the survival of dopaminergic neurons in vitro |
| Q45921946 | [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice]. |
| Q47252585 | eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs |
Search more.